We previously showed that ANG II induces mesangial cell (MC) proliferation via the JNK-activator protein-1 pathway. The present study attempted to determine the upstream mediators of JNK activation, with emphasis on reactive oxygen species (ROS) and the epidermal growth factor (EGF) receptor (EGFR). In cultured human MCs (HMCs), as early as 3 min, ANG II time dependently increased intracellular ROS production, which was sensitive to 10 M diphenyleneiodonium sulfate and 500 M apocynin, two structurally distinct NADPH oxidase inhibitors. In contrast, inhibitors of other oxidant-producing enzymes, including the mitochondrial complex I inhibitor rotenone, the xanthine oxidase inhibitor allopurinol, the cyclooxygenase inhibitor indomethacin, the lipoxygenase inhibitor nordihydroguiaretic acid, the cytochrome P-450 oxygenase inhibitor ketoconazole, and the nitric oxide synthase inhibitor N G -nitro-L-arginine methyl ester, were without effect. ANG II-induced ROS generation was inhibited by the angiotensin type 1 receptor antagonist losartan (10 M) but not the angiotensin type 2 receptor antagonist PD-123319 (10 M). ANG II induced translocation of p47 phox and p67 phox from the cytosol to the membrane. The antioxidants almost abolished the ANG II mitogenic response, as assessed by [ 3 H]thymidine incorporation and cell number, associated with a remarkable blockade of the activation of EGFR (90% inhibition) and JNK (83% inhibition). The EGFR inhibitor AG-1478 was able to mimic the effect of antioxidants, in that it inhibited the mitogenic response and the JNK activation following ANG II treatment. Together, these data suggest that the ROS-EGFR-JNK pathway is involved in transducing the proliferative effect of ANG II in cultured HMCs.
the renin-angiotensin axis, namely, angiotensin-converting enzyme inhibitors (ACEi) and angiotensin type 1 (AT 1 ) receptor antagonists (ARBs), has become a standard clinical practice for treatment of CKD (27, 36, 41) . Despite intensive investigation, the mechanism of the renal beneficial effects of ACEi and ARBs is incompletely understood. It is clear, however, that these effects of ACEi and ARBs cannot be entirely attributed to their hemodynamic effects (22, 24) . Consistent with this notion, ANG II exerts a direct detrimental effect in the renal cells. In particular, ANG II stimulates proliferation of mesangial cells (MCs) (1, 18, 21, 31, 33, 34, 46) , a hallmark of the pathological changes in CKD. Therefore, it is imperative to understand the signaling mechanism of the ANG II-elicited growth-promoting effect in the MCs.
MAPKs, a family of Ser/Thr protein kinases, are an important part of intracellular signaling pathways connecting extracellular signals to intracellular regulatory proteins. This family consists of three major members, ERK1/2, JNK, and p38. ERK1/2 is typically stimulated by growth factor acting via a tyrosine kinase receptor and is involved in regulation of cell proliferation, whereas JNK and p38 are more preferentially activated by cellular stress and implicated in the regulation of survival, apoptosis, and differentiation. Indeed, in MCs, ERK1/2 has been implicated in mediating the proliferative effect of basic fibroblast growth factor, one of the major players in MC proliferation (21) . However, we recently reported an unexpected finding that MC proliferation in response to ANG II is mediated by JNK, but not ERK1/2 or p38, although all three MAPKs can be activated by ANG II (47) . The following question arises: What signaling mechanism is responsible for ANG II-induced JNK activation in human MCs (HMCs).
The predominant signaling events upstream of MAPK activation in response to ANG II in MCs appear to involve generation of reactive oxygen species (ROS) and subsequent transactivation of the epidermal growth factor (EGF) receptor (EGFR). ROS have been identified as a major contributor of ANG II-induced mitogenic effects in vascular smooth muscle cells (VSMCs) as well as MCs (7, 16, 23) . The sources of ROS production in response to ANG II include, but may not be limited to, NAD(P)H oxidase (12, 14) . The precise mechanism of redox-dependent regulation of cell function, such as cell growth, is not clear given the wide range of proteins that can be targeted by ROS. However, of particular interest is redox-dependent activation of receptor tyrosine kinases (7) . EGFR is a redox-sensitive tyrosine kinase that is transactivated by ANG II in VSMCs (8, 44) as well as MCs (29, 32, 42) . The transactivation of EGFR by ANG II in MCs involves heparinbinding EGF shedding via metalloproteinase and leads to ERK1/2 activation (42) . The goal of the present study was to determine whether redox-dependent EGFR transactivation is responsible for JNK activation and cell growth in response to ANG II treatment.
MATERIALS AND METHODS
Materials. ANG II, glucose oxidase (GO), diphenyleneiodonium (DPI), apocynin, rotenone (ROT), allopurinol (ALLO), indomethacin phox , and p67 phox from Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were purchased from Sigma.
HMC isolation and culture. HMCs were established and characterized in our laboratory as previously reported. Briefly, cells were grown until confluent in RPMI 1640 medium buffered with 10 mmol/l HEPES to pH 7.4 and supplemented with 10% FCS, 5 g/ml insulin and transferrin, 100 U/ml penicillin, and 100 mg/ml streptomycin. For passage, confluent cells were washed with PBS, removed with 0.025% trypsin-0.5 mM EDTA in PBS, and plated in RPMI 1640 medium. Experiments were performed on cells between passages 5 and 10.
Western blot analysis. At indicated time points, HMCs were rapidly washed with ice-cold PBS and lysed for 10 min on ice in lysis buffer (50 mM Tris, pH 7.5, 40 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 g/ml leupeptin, 2 mM DTT, and 1 mM PMSF). Lysates were cleared by centrifugation at 14,000 g (4°C) for 10 min. Total proteins were quantified by the Bradford assay. Equal amounts of lysates were fractionated by 15% SDS-PAGE and electrotransferred to Bio-Blot nitrocellulose membranes (Bio-Rad). The membranes were blocked in TBST (20 mM Tris base, pH 7.6, 150 mM NaCl, and 0.1% Tween 20) containing 5% bovine serum albumin for 1 h at room temperature and incubated overnight with a primary antibody in the blocking solution at 4°C. The membranes were incubated for 1 h with 3 H]thymidine into TCA-insoluble material was measured by a liquid scintillation spectrophotometer. For assay of cell growth, HMCs in six-well plates were treated as described above, and cells were counted using a Coulter counter.
DCFDA measurement of ROS. The fluorogenic substrate DCFDA, a cell-permeable dye that is oxidized to highly fluorescent DCF by H 2O2, has been commonly used to monitor intracellular generation of ROS (13, 17, 43, 48, 49) . For measurement of ROS, cells were grown on glass coverslips. When the cells reached confluence, they were washed twice with PBS and incubated for 30 min with 50 M DCFDA diluted in RPMI 1640 medium with 10% FCS. Then the cells were treated with ANG II in the presence or absence of DPI, apocynin, ROT, ALLO, INDO, L-NAME, NDGA, or KETO. At the end of the incubation period, the cells were washed twice with PBS and imaged using confocal laser microscopy. For quantitation of ROS levels, the cells were seeded onto a 96-well plate and treated as described above. Relative fluorescence was measured using a fluorescence plate reader (FLUOstar OPTIMA) at excitation and emission wavelengths of 485 and 528 nm, respectively. The following agents were used to assess potential sources of ROS production: DPI, a flavoprotein inhibitor (10 M); apocynin, an NADPH oxidase inhibitor (500 M); the complex I mitochondrial electron chain inhibitor ROT (10 M); the xanthine oxidase inhibitor ALLO (30 M); the cyclooxygenase inhibitor INDO (100 M); the lipoxygenase inhibitor NDGA (10 M); the cytochrome P-450 oxygenase inhibitor KETO (10 M); and the nitric oxide synthase inhibitor L-NAME (100 M).
Lucigenin chemiluminescence. Superoxide (O 2 •Ϫ ) production in cell homogenates was measured with lucigenin-enhanced chemiluminescence in a microplate luminometer (Anthos Lucy 1). Briefly, HMCs were detached, washed in PBS, and resuspended in 400 l of buffer (50 mmol/l KH 2PO4, 1 mmol/l EGTA, and 150 mmol/l sucrose, pH 7.0) with a protease inhibitor cocktail. Cells were sonicated and distributed in triplicate (10 g/well) onto a 96-well microplate. NADPH (300 mol/l) and dark-adapted lucigenin (5 mol/l) were added to wells just before they were read. O 2
•Ϫ production was expressed as arbitrary light units over 20 min.
Statistical analysis. Values are means Ϯ SE from at least three separate experiments. Statistical comparisons between two groups and multiple groups were done by Student's t-test and one-way ANOVA, respectively, using SPSS 10.0. P Ͻ 0.05 was considered to represent statistical significance.
RESULTS
Effect of ANG II on ROS production. Using DCFDA and fluorescence microscopy, we initially validated the time course of ROS production in response to ANG II treatment in cultured HMCs. As shown in Fig. 1 , ANG II elevated the intensity of fluorescence (n ϭ 8 for each) as early as 3 min, which gradually increased and peaked at 1 h.
HMCs express AT 1 and AT 2 receptors. To examine the type of receptors involved, HMCs were treated with the AT 1 antagonist losartan (10 M) or the AT 2 antagonist PD-123319 (10 M) for 30 min and then with 100 nM ANG II for 1 h. ANG II-induced ROS production was inhibited by losartan, but not PD-123319 (Fig. 1J) , indicating involvement of AT 1 , but not AT 2 , receptors.
Enzymatic sources of ANG II-induced ROS production. To determine the enzymatic sources of ROS, we measured ANG II-induced ROS production in the presence and absence of inhibitors of various oxidant-producing enzymes. As shown in Fig. 2 , respectively, n ϭ 6 for each group; Fig. 3A) .
Activation of NADPH oxidase requires translocation of the cytosolic components, including p47 phox and p67 phox , to the cell membrane. Therefore, using immunoblotting analysis of Fig. 3 . NADPH oxidase activity and membranous translocation of p47 phox and p67 phox in HMCs. A: NADPH oxidase activity. Confluent HMCs in 6-well plates were pretreated for 30 min with 10 M losartan, 500 M apocynin, or 10 M DPI and, for a further 2 h, with 100 nM ANG II, and NADPH oxidase-dependent O2
•Ϫ production by intact HMCs was measured by lucigenin-enhanced chemiluminescence. RLU, relative light units. B and C: membranous translocation of p47 phox and p67 phox . HMCs were treated as described in A, and fractionated membranous proteins and whole cell lysates were subjected to immunoblot analysis of p47 phox and p67 phox . Values are means Ϯ SE (n ϭ 3). *P Ͻ 0.01 vs. control. †P Ͻ 0.01 vs. ANG II.
fractionated cellular proteins, we examined the effects of ANG II on membranous translocation of p47 phox and p67 phox in HMCs. As shown in Fig. 4 , B and C, treatment with 100 nM ANG II for 2 h induced increased p47 phox and p67 phox protein levels in the membranous fraction by 3.72-and 3.86-fold, respectively, but had no effect on their total protein abundance. ANG II-induced membranous translocation of p47 phox and p67 phox was markedly attenuated by 10 M losartan, 500 M apocynin, or 10 M DPI (Fig. 3, B and C) .
Role of ROS in ANG II-induced HMC proliferation.
To test the role of ROS in ANG II-induced HMC proliferation, we performed experiments to determine 1) whether exogenous ROS stimulated HMC proliferation, mimicking the effect of ANG II, and 2) whether inhibition of endogenous ROS production by antioxidants blocked the effect of ANG II. We first examined responsiveness of HMCs to exogenous ROS produced by the glucose-GO system, which is known to continuously produce H 2 O 2 in a glucose-containing medium (10, 38) . Addition of GO (1 mU/ml) significantly induced HMC proliferation, as determined by [ 3 H]thymidine incorporation and cell number (Fig. 4) . We subsequently examined the role of ROS in ANG II-induced HMC proliferation. HMCs were pretreated with losartan, NAC, or the NADPH oxidase inhibitor apocynin and DPI for 30 min and then incubated with 100 nM ANG II for 48 h. Losartan, NAC, apocynin, and DPI effectively inhibited ANG II-induced HMC proliferation (Fig. 5) .
Involvement of ROS in ANG II-induced transactivation of EGFR.
Transactivation of EGFR is a major mechanism responsible for the growth-promoting effect of ANG II. We examined the role of ROS in ANG II-induced EGFR transactivation. We first examined the transactivation kinetics of EGFR after treatment with 100 nM ANG II. EGFR transactivation was determined by immunoblotting with use of an antibody recognizing the phosphorylated (Tyr 1068 ) EGFR that is responsible for MAPK activation and EGFR activity. ANG II increased the level of phosphorylated EGFR at 5 min, with maximal stimulation at 30 min (Fig. 6A) . Therefore, the 30-min time point was used in subsequent experiments for determination of the dose response of ANG II stimulation of EGFR. As shown in Fig. 6B , ANG II increased phosphorylation of EGFR in a dose-dependent manner, with maximal stimulation at 100 nM. Pretreatment with losartan significantly blocked ANG II-induced EGFR transactivation (Fig. 7) . We then examined the effects of antioxidants on ANG II-induced EGFR transactivation. NAC, apocynin, or DPI completely blocked ANG IIinduced phosphorylation of EGFR (Fig. 7) . (Fig. 8) . Consistent with this finding, ANG II-induced HMC proliferation was completely inhibited by AG-1478 (Fig. 9) .
DISCUSSION
ANG II stimulates MC proliferation, but the underlying mechanism remains incompletely understood. Our previous study provides evidence for involvement of JNK, but not ERK1/2 or p38, in the ANG II-induced mitogenic effect in cultured HMCs (47) . All three MAPKs were activated by ANG II, but only the JNK inhibitor SP-600125 blocked the mitogenic effect of ANG II. The present study extended this observation by identifying the upstream mediators of JNK activation, including ROS and EGFR. We found that ANG II, via AT 1 , but not AT 2 , receptors, increased intracellular ROS production in cultured HMCs associated with membranous translocation of p47 phox and p67 phox . ANG II-induced ROS release was almost completely blocked by DPI and apocynin, two structurally distinct NADPH oxidase inhibitors, but was unaffected by inhibitors of the other oxidant-producing enzyme systems. The NADPH oxidase inhibitors and NAC remarkably inhibited JNK activation, as well as MC proliferation, in response to ANG II treatment. These findings suggest involvement of NADPH oxidase-derived ROS in ANG II-induced JNK activation in cultured HMCs. ROS appeared to activate JNK through EGFR, inasmuch as antioxidants prevented the transactivation of EGFR and inhibition of EGFR by AG-1478 significantly inhibited JNK activation. Together, these obser- vations suggest that the ROS-EGFR-JNK pathway transduces the signaling of the ANG II-induced proliferating effect in cultured HMCs.
Previously considered as only toxic by-products of metabolisms, ROS are now well appreciated as important signaling molecules involved in a wide variety of physiological and pathological processes (4, 20, 39) . ROS have been shown to mediate MC contraction (40) , hypertrophy (14) , and apoptosis (26) in response to ANG II treatment. Therefore, it is of critical importance to clarify the source of ANG II-induced ROS generation in MCs. Additionally, no previous studies have directly addressed the role of ROS in the ANG II-induced mitogenic effect in these cells. Therefore, a major aim of the present study was to determine the source of ROS generation relevant to the ANG II-induced mitogenic effect in cultured HMCs. NADPH oxidase is a multicomponent enzyme consisting of the membrane-associated subunits p22 phox and gp91 phox and the cytosolic subunits p47 phox , p67 phox , and p40 phox , and the activity of the enzyme requires translocation of the cytosolic complex to the membrane (9, 11, 19) . In recent years, four homologs of gp91 phox (Nox2), Nox1 (37), Nox3, Nox4, and Nox5 (25) , have been identified. NADPH oxidase is a major O 2
•Ϫ -generating enzyme in phagocytes as well as nonphagocytic cells. After NADPH oxidase, there is a growing list of other oxidant-generating systems that contribute to ROS production under various conditions; these systems include the mitochondrial respiratory chain, xanthine oxidase, cyclooxygenase, lipoxygenase, cytochrome P-450, and nitric oxide synthase. We found that ANG II-induced ROS release was almost completely blocked by the NADPH oxidase inhibitors DPI and apocynin, but the mitochondrial complex I inhibitor ROT, the xanthine oxidase inhibitor ALLO, the cyclooxygenase inhibitor INDO, the lipoxygenase inhibitor NDGA, the cytochrome P-450 oxygenase inhibitor KETO, and the nitric oxide synthase inhibitor L-NAME were without effect. To our knowledge, this is the most comprehensive investigation of the respective contribution of various oxidant systems to ANG II-induced ROS production in cultured MCs. Not only did the NADPH oxidase inhibitors inhibit ROS production, but these compounds also blocked the proliferative effect of ANG II. In addition to the pharmacological evidence favoring NADPH oxidase as a major source of ANG II-induced ROS production, we also provided evidence for translocation of p47 phox and p67 phox to the membrane in response to ANG II treatment. These findings are in agreement with the previous observation that ANG II activates NADPH oxidase in cultured MCs (2, 15) .
The molecular target of ROS in the ANG II-elicited signaling pathway in cultured HMCs appears to be EGFR. In support of this notion, exposure of HMCs to ANG II activated EGFR, as evidenced by a rapid increase in phosphorylation of the receptor. Activation of EGFR was completely prevented by antioxidants, including inhibitors of NADPH oxidase. Furthermore, the EGFR inhibitor AG-1478 was able to mimic the effect of antioxidants in attenuating ANG II-induced MC proliferation. It has been reported that the redox-dependent transactivation of EGFR is a major mechanism by which ANG II induces proliferative/hypertrophic effects in VSMCs (30, 44, 45) . Our findings suggest that the same mechanism may be operative in cultured HMCs.
We have provided evidence that JNK represents a downstream mediator of ROS-dependent activation of EGFR in the ANG II-induced signaling pathway in cultured HMCs. This notion is based on the observation that ANG II-induced activation of JNK was inhibited by antioxidants and the EGFR inhibitor AG-1478. This is somewhat different from the observation in VSMCs (5) and rat neonatal cardiomyocytes (28) that transactivation of EGFR is required for ANG II-induced activation of ERK1/2 and p38, but not JNK. The reason for this discrepancy is unclear but may indicate a cell type-specific phenomenon.
In summary, our previous study demonstrated that JNK mediates ANG II-induced HMC proliferation, and the present study has extended this observation by examining ROS and EGFR as upstream mediators of the JNK activation. We found that ANG II, via AT 1 , but not AT 2 , receptors increased NADPH oxidase-dependent production of ROS, which activates EGFR, leading to activation of JNK. The elucidation the proliferative response to ANG II in HMCs of the ROS-EGFR-JNK pathway provides insights into mechanisms of MC proliferation and may also help identify new targets for treatment of glomerular diseases.
